Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late Boost on HIV-uninfected Vaccinees From EV06 Trial
NCT03391375Phase 1Completed
- Sponsor
- EuroVacc Foundation
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DNA-HIV-PT123 and AIDSVAX B/E in human immunodeficiency virus infection (HIV), sponsored by EuroVacc Foundation. Primary endpoints: Vaccine induced binding antibody responses at 24 weeks, Vaccine induced neutralizing antibody responses at 24 weeks and 1 more. Started Mar 2017; status: completed.
02
Drugs
DNA-HIV-PT123AIDSVAX B/E
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03391375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03391375.